These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1977316)

  • 21. Comparison of famotidine with cimetidine and ranitidine.
    Berardi RR; Tankanow RM; Nostrant TT
    Clin Pharm; 1988 Apr; 7(4):271-84. PubMed ID: 2896559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacology of H2-receptor antagonists: an overview.
    Schunack W
    J Int Med Res; 1989; 17 Suppl 1():9A-16A. PubMed ID: 2566544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical importance of the new H2-antagonists.
    Walt RP
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():97-9. PubMed ID: 2566730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
    Poynard T; Lemaire M; Agostini H
    Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-purpose evaluation of H2-antagonist usage.
    Gianarkis D
    Hosp Formul; 1992 May; 27(5):527-30, 532. PubMed ID: 10117769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multidisciplinary process to determine, communicate, and manage an antibiotic formulary.
    Cook AA; Sanchez ML
    Hosp Pharm; 1992 Oct; 27(10):867-9, 872-4, 882. PubMed ID: 10121423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of the effect of omeprazole, cimetidine, famotidine and ranitidine on histamine induced cutaneous wheal and flare response.
    Saha N; Sachdev A; Bhasin DK; Sankaranahyanan A; Khosla PP; Singh K; Sharma PL
    Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):322-5. PubMed ID: 8103763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computer-based support system for formulary decisions.
    Senthilkumaran K; Shatz SM; Kalies RF
    Am J Hosp Pharm; 1987 Jun; 44(6):1362-6. PubMed ID: 3618613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical appropriateness, therapeutic equivalence, and cost of conversion of H2 antagonist therapy.
    Kitrenos JG; Brown DR; Letting DJ; Rotella DL
    Hosp Formul; 1993 Jan; 28(1):86-8, 91, 95-6. PubMed ID: 10123271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level.
    Ohsawa T; Hirata W; Higichi S
    Int J Clin Pharmacol Res; 2002; 22(2):29-35. PubMed ID: 12503773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacist adjustment of H2-receptor antagonist dosage to meet medical staff-approved criteria.
    Malcolm KE; Griffin CR; Bennett TA; Robertson LM
    Am J Hosp Pharm; 1994 Sep; 51(17):2152-4. PubMed ID: 7985692
    [No Abstract]   [Full Text] [Related]  

  • 32. Decision analysis applied to pharmacy practice.
    Einarson TR; McGhan WF; Bootman JL
    Am J Hosp Pharm; 1985 Feb; 42(2):364-71. PubMed ID: 3919578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bar-code technology applied to drug-use evaluation.
    Zarowitz BJ; Petitta A; Mlynarek M; Touchette M; Peters M; Long P; Patel R
    Am J Hosp Pharm; 1993 May; 50(5):935-9. PubMed ID: 8099468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacology of histamine H2-receptor antagonists.
    Mills JG; Wood JR
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():87-95. PubMed ID: 2566729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomic aspects and formulary considerations related to histamine2-receptor antagonists.
    Souney PF; Stoukides CA
    DICP; 1989 Oct; 23(10 Suppl):S29-35. PubMed ID: 2573207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Formulary decision making: identifying factors that influence P&T committee drug evaluations.
    Segal R; Pathak DS
    Hosp Formul; 1988 Feb; 23(2):174-8. PubMed ID: 10286022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of some of the pharmacological properties of etintidine, a new histamine H2-receptor antagonist, with those of cimetidine, ranitidine and tiotidine.
    Cavanagh RL; Usakewicz JJ; Buyniski JP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):171-9. PubMed ID: 6129316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].
    Simon B; Müller P; Dammann HG
    Wien Med Wochenschr; 1982 May; 132(10):223-8. PubMed ID: 6126962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro availability studies of enoxacin in presence of H2 receptor antagonists.
    Arayne MS; Sultana N; Haroon U; Hamza E
    Pak J Pharm Sci; 2007 Jul; 20(3):235-43. PubMed ID: 17545110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurotoxic convulsions induced by histamine H2 receptor antagonists in mice.
    Shimokawa M; Yamamoto K; Kawakami J; Sawada Y; Iga T
    Toxicol Appl Pharmacol; 1996 Feb; 136(2):317-23. PubMed ID: 8619239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.